011000.KS
GeneOne Life Science, Inc.
KSEKRWEQUITY
DELAYED
Last price
534.00
▼ 2,136.00 (80.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
2,670.00
Day high
534.00
Day low
534.00
Volume
—
Market cap
—
P/E (TTM)
—
52W range
534.00 – 13,425.00
Trailing performance
Returnvs SPY
1W
0.00%
+1.4%
1M
0.00%
-3.7%
3M
-67.32%
-70.4%
6M
-69.13%
-80.2%
YTD
-72.74%
-85.0%
1Y
-76.98%
-97.0%
3Y
-85.37%
-159.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on 011000.KS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $23.04B | $35.72B | $40.20B | $48.72B | -35.5% |
| Operating revenue | $23.04B | $35.72B | $40.20B | $48.72B | -35.5% |
| Cost of revenue | $38.18B | $46.59B | $47.96B | $39.38B | -18.0% |
| Gross profit | -$15.14B | -$10.87B | -$7.76B | $9.34B | -39.3% |
| Research & development | $1.93B | $3.56B | $7.04B | $12.15B | -45.8% |
| Selling, general & admin | $7.66B | $6.02B | $7.54B | $7.45B | +27.3% |
| Total operating expense | $33.64B | $37.33B | $40.61B | $49.42B | -9.9% |
| Operating income | -$48.77B | -$48.20B | -$48.37B | -$40.08B | -1.2% |
| Net interest income | -$4.95B | -$2.03B | -$660.95M | -$1.09B | -143.9% |
| Pre-tax income | -$51.94B | -$48.75B | -$77.65B | -$38.05B | -6.5% |
| Tax provision | -$86.36M | -$216.19M | $113.45M | $95.79M | +60.1% |
| Net income | -$51.85B | -$48.54B | -$77.77B | -$38.15B | -6.8% |
| Net income to common | -$51.85B | -$48.54B | -$77.77B | -$38.15B | -6.8% |
| Basic EPS | -3,145.00 | -3,055.00 | -5,000.00 | -2,460.00 | -2.9% |
| Diluted EPS | -3,145.00 | -3,055.00 | -5,000.00 | -2,460.00 | -2.9% |
| EBIT | -$46.80B | -$46.60B | -$76.47B | -$30.74B | -0.4% |
| EBITDA | -$28.60B | -$28.64B | -$63.70B | -$25.32B | +0.1% |
| Basic shares | 16.49M | 15.89M | 15.55M | 15.51M | +3.8% |
| Diluted shares | 16.49M | 15.89M | 15.55M | 15.51M | +3.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.32B | $1.18B | $9.11B | $13.26B | +11.7% |
| Cash & short-term investments | $1.73B | $1.75B | $9.99B | $45.60B | -0.7% |
| Accounts receivable | $1.74B | $7.18B | $6.62B | $8.98B | -75.8% |
| Inventory | $13.42B | $16.51B | $14.90B | $14.86B | -18.7% |
| Total current assets | $19.44B | $28.64B | $34.57B | $73.06B | -32.1% |
| Property, plant & equipment | $95.40B | $117.73B | $111.40B | $144.37B | -19.0% |
| Goodwill & intangibles | $208.41M | $189.96M | $385.99M | $563.91M | +9.7% |
| Total assets | $119.21B | $151.33B | $151.01B | $222.87B | -21.2% |
| Total current liabilities | $53.81B | $42.51B | $22.87B | $33.84B | +26.6% |
| Current debt | $9.20B | $3.38B | $2.41B | $12.25B | +172.4% |
| Long-term debt | $20.02B | $16.37B | $6.27B | — | +22.3% |
| Total debt | $32.96B | $27.13B | $17.16B | $19.67B | +21.5% |
| Total liabilities | $78.31B | $65.73B | $39.52B | $41.40B | +19.1% |
| Retained earnings | -$316.84B | -$264.85B | -$216.23B | -$137.16B | -19.6% |
| Shareholder equity | $40.90B | $85.61B | $111.49B | $181.47B | -52.2% |
| Working capital | -$34.37B | -$13.87B | $11.71B | $39.23B | -147.8% |
| Net tangible assets | $40.69B | $85.42B | $111.10B | $180.91B | -52.4% |
| Shares issued | 17.04M | 16.01M | 15.69M | 15.55M | +6.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$51.85B | -$48.54B | -$77.77B | -$38.15B | -6.8% |
| Depreciation & amortisation | $18.20B | $17.96B | $12.78B | $5.42B | +1.3% |
| Change in working capital | $5.99B | $6.07B | $8.62B | $3.74B | -1.3% |
| Operating cash flow | -$16.54B | -$16.06B | -$21.74B | -$24.11B | -3.0% |
| Capital expenditure | -$59.07M | -$3.37B | -$5.65B | -$45.41B | +98.2% |
| Investing cash flow | -$769.89M | -$2.85B | $25.89B | $8.06B | +72.9% |
| Financing cash flow | $17.45B | $10.96B | -$8.29B | $7.01B | +59.2% |
| Free cash flow | -$16.60B | -$19.42B | -$27.40B | -$69.52B | +14.5% |
| End cash position | $1.32B | $1.18B | $9.11B | $13.26B | +11.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $2.58B | $2.65B | $5.08B | $6.81B | $8.50B | — | -2.7% |
| Operating revenue | $2.58B | $2.65B | $5.08B | $6.81B | $8.50B | — | -2.7% |
| Cost of revenue | $2.54B | $9.05B | $8.84B | $10.02B | $10.27B | — | -72.0% |
| Gross profit | $44.46M | -$6.40B | -$3.77B | -$3.20B | -$1.76B | — | +100.7% |
| Research & development | $5.93M | $289.06M | $659.29M | $213.12M | $767.37M | — | -97.9% |
| Selling, general & admin | $996.31M | $3.11B | $1.65B | $1.47B | $1.42B | — | -68.0% |
| Total operating expense | $2.39B | $6.72B | $7.90B | $11.72B | $7.30B | — | -64.5% |
| Operating income | -$2.34B | -$13.12B | -$11.66B | -$14.92B | -$9.07B | — | +82.1% |
| Net interest income | -$163.75M | -$3.12B | -$614.40M | -$602.80M | -$621.06M | — | +94.7% |
| Pre-tax income | -$2.38B | -$16.24B | -$11.48B | -$15.41B | -$8.81B | — | +85.3% |
| Tax provision | — | -$100.93M | -$7.89M | -$388.89K | $22.85M | -$249.14M | — |
| Net income | -$2.38B | -$16.14B | -$11.47B | -$15.41B | -$8.84B | — | +85.2% |
| Net income to common | -$2.38B | -$16.14B | -$11.47B | -$15.41B | -$8.84B | — | +85.2% |
| Basic EPS | -135.00 | — | -675.00 | -935.00 | -555.00 | — | — |
| Diluted EPS | -135.00 | — | -675.00 | -935.00 | -555.00 | — | — |
| EBIT | -$2.17B | -$13.03B | -$10.83B | -$14.77B | -$8.17B | — | +83.4% |
| EBITDA | -$1.86B | -$8.47B | -$6.39B | -$10.25B | -$3.49B | — | +78.0% |
| Basic shares | 18.18M | — | 16.97M | 16.53M | 15.92M | — | — |
| Diluted shares | 18.18M | — | 16.97M | 16.53M | 15.92M | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.30B | $1.32B | $985.85M | $749.78M | $1.20B | +301.8% |
| Cash & short-term investments | $5.72B | $1.73B | $2.71B | $2.72B | $3.94B | +230.0% |
| Accounts receivable | $1.98B | $1.74B | $3.98B | $5.10B | $4.93B | +13.6% |
| Inventory | $13.12B | $13.42B | $15.40B | $15.44B | $16.65B | -2.2% |
| Total current assets | $24.67B | $19.44B | $23.84B | $24.91B | $27.56B | +26.9% |
| Property, plant & equipment | $102.05B | $95.40B | $97.78B | $97.87B | $112.77B | +7.0% |
| Goodwill & intangibles | $218.14M | $208.41M | $197.35M | $184.75M | $195.88M | +4.7% |
| Total assets | $131.29B | $119.21B | $125.54B | $126.67B | $144.23B | +10.1% |
| Total current liabilities | $53.92B | $53.81B | $47.98B | $43.39B | $43.82B | +0.2% |
| Current debt | $9.39B | $9.20B | $8.02B | $4.46B | $5.31B | +2.1% |
| Long-term debt | $21.11B | $20.02B | $17.04B | $15.64B | $18.06B | +5.5% |
| Total debt | $34.15B | $32.96B | $30.38B | $25.89B | $30.17B | +3.6% |
| Total liabilities | $80.13B | $78.31B | $70.19B | $64.18B | $67.86B | +2.3% |
| Retained earnings | -$319.22B | -$316.84B | -$300.56B | -$289.09B | -$273.69B | -0.8% |
| Shareholder equity | $51.15B | $40.90B | $55.36B | $62.49B | $76.38B | +25.1% |
| Working capital | -$29.25B | -$34.37B | -$24.13B | -$18.48B | -$16.26B | +14.9% |
| Net tangible assets | $50.94B | $40.69B | $55.16B | $62.31B | $76.18B | +25.2% |
| Shares issued | 18.18M | 17.04M | 17.08M | 16.98M | 16.01M | +6.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$2.38B | -$16.14B | -$11.47B | -$15.41B | -$8.84B | — | +85.2% |
| Depreciation & amortisation | $307.70M | $4.56B | $4.44B | $4.52B | $4.68B | — | -93.3% |
| Change in working capital | -$856.28M | $5.69B | $2.36B | -$2.25B | $188.46M | — | -115.0% |
| Operating cash flow | -$2.84B | -$1.77B | -$3.61B | -$7.68B | -$3.48B | — | -60.9% |
| Capital expenditure | — | -$28.33M | -$10.79M | — | -$69.14M | -$1.67B | — |
| Investing cash flow | -$666.51M | -$314.28M | -$798.69M | -$193.86M | $536.94M | — | -112.1% |
| Financing cash flow | $7.49B | $2.41B | $4.65B | $7.43B | $2.96B | — | +210.1% |
| Free cash flow | -$2.84B | -$1.79B | -$3.62B | -$7.63B | -$3.55B | — | -58.3% |
| End cash position | $5.30B | $1.32B | $985.85M | $749.78M | $1.20B | — | +301.8% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2,670.00
-80.00% from price
SMA 20
2,670.00
0.00% from price
SMA 50
2,915.60
-8.42% from price
SMA 100
3,988.95
-86.61% from price
SMA 200
6,396.08
-58.26% from price
EMA 12
2,671.55
-80.01% from price
EMA 26
2,755.88
-80.62% from price
EMA 50
3,135.13
-82.97% from price
RSI (14)
27.5
Oversold
MACD (12,26,9)
-84.32
Hist 36.56
ATR (14)
0.00
—
Realised vol 30D
0.0%
Annualised
Bollinger upper
2,670.00
20, 2σ
Bollinger lower
2,670.00
20, 2σ
50 / 200 cross
Death
2,915.60 vs 6,396.08
Trend bias
Below 200
-58.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.65
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
0.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-78.8%
Peak to trough
Max drawdown 5Y
-97.9%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
IHG expands Japanese footprint with 14-hotel conversion deal
Hotel Management Network · 2m ago
The New Flat Rate releases latest average Tennessee home repair costs
PR Newswire · 3m ago
Net Asset Value(s)
Business Wire · 5m ago
SLB Launches ExaCT Electrical Downhole CT Control System
Business Wire · 5m ago
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
PR Newswire · 5m ago
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets
ACCESS Newswire · 6m ago
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI
Business Wire · 6m ago
Is Fidelity Select Utilities (FSUTX) a Strong Mutual Fund Pick Right Now?
Zacks · 7m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.